A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 26, 2016

Primary Completion Date

May 24, 2016

Study Completion Date

May 24, 2016

Conditions

HIV Infections

Interventions

DRUG

Oral BMS-663068 (pro-drug)

Oral BMS-663068 (pro-drug), metabolized to active BMS-626529

Trial Locations (1)

GSK Investigational Site, Miami